The treatment of hemorrhagic shock with WR-149,024 (1,18-diamino-6,13-diaza-9,10-dithiaoctadecane tetrahydrochloride).
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000818:Animals; D001794:Blood Pressure; D001798:Blood Proteins; D001804:Blood Transfusion, Autologous; D001810:Blood Volume; D006328:Cardiac Catheterization; D002302:Cardiac Output; D002404:Catheterization; D002496:Central Venous Pressure; D002860:Chromium Radioisotopes; D004220:Disulfides / Q000627:therapeutic use*; D004285:Dogs; D004562:Electrocardiography; D005260:Female; D000882:Haplorhini; D006339:Heart Rate; D006400:Hematocrit; D006493:Heparin / Q000494:pharmacology; D008297:Male; D011073:Polyamines / Q000627:therapeutic use*; D012771:Shock, Hemorrhagic / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; D001798:Blood Proteins; D002860:Chromium Radioisotopes; D004220:Disulfides; D011073:Polyamines; D006493:Heparin